Navigation Links
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Date:2/28/2011

0 mg, 8.8% with ARCALYST 80 mg, and 7.6% with placebo), lower respiratory tract infection (0% with ARCALYST 160 mg, 5.0% with ARCALYST 80 mg, and 2.5% with placebo), musculoskeletal pain/discomfort (6.2% with ARCALYST 160 mg, 7.5% with ARCALYST 80 mg, and 8.9% with placebo), and headache, (3.7% with ARCALYST 160 mg, 6.3% with ARCALYST 80 mg, and 1.3% with placebo).

About the RE-SURGE StudyThe global RE-SURGE (REview of Safety Using Rilonacept in preventing Gout Exacerbations) study, was a double-blind, placebo-controlled study primarily focused on evaluation of safety. The trial was conducted in the United States, South Africa, Germany, and parts of Asia.  A total of 1,315 patients who were at risk for gout flares because they were initiating or taking uric acid-lowering drug treatment were randomly assigned in a 1:3 ratio to receive either weekly placebo injections (n=330) for 16 weeks or weekly subcutaneous injections of ARCALYST dosed at 320 mg as an initial loading dose and 160 mg thereafter (n=985) for a total of 16 weeks.  In this trial, a gout flare was defined as patient-reported acute articular pain typical of a gout attack that was deemed (by the patient and/or the investigator) to require treatment with an anti-inflammatory therapeutic.

Overall, the cumulative rate of infections was 20.1% in patients treated with ARCALYST and 19.1% in placebo patients.  Serious infections were reported in 0.5% of patients treated with ARCALYST® (rilonacept) and 0.9% of placebo patients.  Deaths were reported for 0.3% of patients treated with ARCALYST and 0.9% of placebo patients.

Specific adverse events that occurred at a frequency of at least 5% in any study group were: injection site reaction (15.2% with ARCALYST and 3.3 % with placebo), musculoskeletal pain/ discomfort (11.2% with ARCALYST and 9.7% with placebo), headaches (9.5% with ARCALYST and 8.8% with placebo), joint
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
2. New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays
3. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
7. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
9. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
10. MADIT-CRT Trial Meets Primary Endpoint
11. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... YORK , Sept. 2, 2015 ... is an X-linked disease, which generally affects the ... degeneration and weakness. The disease is caused due ... in the lack of production of dystrophin (a ... individuals. The lack of dystrophin weakens muscle function, ...
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015 ... leukemia is a malignant condition characterized by increased production ... first affects B-lymphocytes and then it can spread to ... mostly at later stages because of the slow buildup ... disease, the malignancy spreads to the spleen, liver, and ...
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has ... China (Basel, Switzerland - November 26-27, 2015)" conference to ... detailed overview of the key areas of pharmaceutical regulatory affairs ... , Macau and ... All important aspects of gaining and maintaining a successful Marketing ...
Breaking Medicine Technology:Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2
... , SAN FRANCISCO , May 18 ... demonstrated patients treated with a standard or low dose of ... in how often they were awakened at night by hot ... presented today at the 58th Annual Clinical Meeting of the ...
... NANJING , China, May 18 /PRNewswire-Asia/ -- ... ), a leading pharmaceutical company,specializing in the development, manufacturing, and ... preliminary,unaudited financial results for the quarter ended March 31, ... -- Total revenue was RMB458.7 million (US$67.2 million) for ...
Cached Medicine Technology:New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 2New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 3New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 4New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 5New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 6New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 7Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 2Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 3Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 4Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 5Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 6Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 7Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 8Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 9Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 10Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 11Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 12
(Date:9/3/2015)... ... 03, 2015 , ... DiabetesSisters Welcomes Carol Wysham to Board ... of Carol Wysham, MD, to their esteemed Board of Directors. Dr. Wysham was ... Warren, Matt Stella, Tricia Cedotal, Andrea Thomas, Wanda Nicholson and Vicki Norris. As ...
(Date:9/3/2015)... ... ... A scar is an unavoidable result of incision or injury to the skin. Unsightly as ... itself. The appearance of a scar is dependent on many factors – the size and ... scars fade to near invisibility on their own over a period of months,” says ...
(Date:9/3/2015)... ... 03, 2015 , ... The new In-Office whitening kit from ... The Clinicians Report is a leading information source to the dental industry. Product ... Whiter Image's In-Office whitening kits were favorably validated for use in the dental ...
(Date:9/3/2015)... ... September 03, 2015 , ... James Earl Jones will be ... In this episode, James Earl Jones will introduce a segment that discusses why it ... and how workplace wellness can be fostered in any working environment. , Employers are ...
(Date:9/2/2015)... ... September 03, 2015 , ... The Aspen Clinic (TAC), located in ... towards kick-starting and inspiring wellness in the Roaring Fork Valley and beyond. , Amanda ... whole mind-body approach to fitness - we are much more than a gym. ...
Breaking Medicine News(10 mins):Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:TAC Introduces New Retreats for Fall Fitness 2
... , ... announces that their Electronic Health Record, Perfect Care EHR® ... Information Technology (CCHIT®) and is Preliminary ARRA 2011 certified, ... Use Objectives for Eligible Providers under the American Recovery ...
... drug cocktail might be the right mix to fight ... Details of a new study supporting this approach suggest ... work again. The findings were presented today at the ... involves post-menopausal women whose advanced breast cancers are fueled ...
... that could prevent another blood clot, study finds , ... stroke survivors don,t take medications that can reduce their risk ... stroke is caused by blocked blood flow in the brain. ... ischemic stroke. These include blood thinners (antithrombotic medications), of which ...
... , , , WINSTON-SALEM, N.C., Dec. 11 ... officers once again put the spotlight on mass murder in ... killings at Fort Hood, the Washington case raised questions about ... rampage. , Andrew Smiler, an assistant professor of psychology at ...
... , DALLAS, Dec. 11 For their ... rehabilitation for younger, more active cardiac patients, the Cardiac ... Heart and Vascular Hospital was recently awarded the Innovation ... Rehabilitation (AACVPR). The award acknowledges programs that have enhanced ...
... survey respondents were under 35 when they sought treatment , ... that age is an important factor in the success of ... 18 and older, including 125 women who,ve had fertility treatment. ... were under age 35 when they first sought medical advice ...
Cached Medicine News:Health News:NCG Medical, Perfect Care EHR Achieves Preliminary ARRA 2011 Certification From CCHIT 2Health News:NCG Medical, Perfect Care EHR Achieves Preliminary ARRA 2011 Certification From CCHIT 3Health News:Clinical trial advances new approach to re-sensitizing breast cancer 2Health News:Mass Murderers: Why Do They Kill? 2Health News:Baylor Hamilton Heart Hospital Honored for Innovative Rehabilitation Program 2Health News:Baylor Hamilton Heart Hospital Honored for Innovative Rehabilitation Program 3Health News:Women Aren't Waiting to Seek Infertility Help 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: